Evidence map›Paper›PMID 39434503›Full record

ArticleBiomaterials science2024

Generation of nanobodies with conformational specificity for tau oligomers that recognize tau aggregates from human Alzheimer's disease samples.

Nikki McArthur, Jay D Squire, Ogechukwu J Onyeachonam, Nemil N Bhatt, Cynthia Jerez, Abigail L Holberton, Peter M Tessier, Levi B Wood, Rakez Kayed, Ravi S Kane

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Biomaterials science, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Review
  3. Structure-specific Mini-Prion Model for Alzheimer's Disease Tau Fibrils.bioRxiv : the preprint server for biology · 2025
    Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Nikki McArthurSchool of Chemical & Biomolecular Engineering, Georgia Institute of Technology, Atlanta, Georgia 30332, USA. ravi.kane@chbe.gatech.edu.ORCID http://orcid.org/0000-0001-9872-8961
Jay D SquireSchool of Chemical & Biomolecular Engineering, Georgia Institute of Technology, Atlanta, Georgia 30332, USA. ravi.kane@chbe.gatech.edu.ORCID http://orcid.org/0009-0007-6908-2533
Ogechukwu J OnyeachonamSchool of Chemical & Biomolecular Engineering, Georgia Institute of Technology, Atlanta, Georgia 30332, USA. ravi.kane@chbe.gatech.edu.
Nemil N BhattMitchell Center for Neurodegenerative Disease, University of Texas Medical Branch, Galveston, Texas 77555, USA.
Cynthia JerezMitchell Center for Neurodegenerative Disease, University of Texas Medical Branch, Galveston, Texas 77555, USA.
Abigail L HolbertonGeorge W. Woodruff School of Mechanical Engineering, Georgia Institute of Technology, Atlanta, Georgia 30332, USA.ORCID http://orcid.org/0009-0004-6719-8426
Peter M TessierDepartment of Chemical Engineering, University of Michigan, North Campus Research Complex, 2800 Plymouth Road, Ann Arbor, MI 48109, USA.
Levi B WoodGeorge W. Woodruff School of Mechanical Engineering, Georgia Institute of Technology, Atlanta, Georgia 30332, USA.
Rakez KayedMitchell Center for Neurodegenerative Disease, University of Texas Medical Branch, Galveston, Texas 77555, USA.
Ravi S KaneSchool of Chemical & Biomolecular Engineering, Georgia Institute of Technology, Atlanta, Georgia 30332, USA. ravi.kane@chbe.gatech.edu.ORCID http://orcid.org/0000-0003-3084-4098

Funding

The Goizueta Alzheimer's Disease Research CenterP30AG066511 · NIA · EMORY UNIVERSITY · PI ALLAN I LEVEY · 2020 to 2026
$29.0M
CD98hc Brain Shuttles for Delivering Off-the-shelf Neuroprotective Antibodies in Alzheimer's DiseaseR01AG080016 · NIA · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI Colin Fred Greineder, Peter M Tessier · 2023 to 2026
$3.2M
Design and Evolution of Polyvalent Domain Antibodies Specific for Tau AggregatesRF1AG059723 · NIA · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI KANE, RAVI S., TESSIER, PETER M · 2018 to 2022
$2.4M
Structure-guided antibody targeting of pre-selected epitopes in amyloidogenic aggregatesR35GM136300 · NIGMS · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI TESSIER, PETER M · 2020 to 2024
$1.5M
Non-invasive and Long-lived CNS Delivery of Treg-inducing Cytokine DepotsR01EB036493 · NIBIB · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI James J. Moon, Peter M Tessier · 2025 to 2026
$1.2M
Long-lived Activation of Parenchymal Border Macrophages Using Immunocytokines to Address Aging- and Alzheimer’s Disease-associated Deficits in Cerebrospinal Fluid DynamicsR21AG093031 · NIA · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI Peter M Tessier · 2025 to 2026
$443k
Efficient and Long-lived Brain Delivery of Neutralizing Antibodies Against Eastern Equine Encephalitis Virus for Post-exposure TherapyR21AI190578 · NIAID · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI Peter M Tessier · 2025 to 2026
$435k
Neuronal Silencing of ATXN3 Using Peripherally Administered Antibody/ASO Conjugates That Penetrate the Blood-Brain BarrierR21NS132018 · NINDS · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI TESSIER, PETER M · 2023 to 2024
$429k
NIAID NIH HHS R21 AI190578NIA NIH HHS P30 AG066511NIA NIH HHS R01 AG080016NIA NIH HHS R21 AG093031NIA NIH HHS RF1 AG059723NIBIB NIH HHS R01 EB036493NIGMS NIH HHS R35 GM136300NINDS NIH HHS R21 NS132018
6 · The paper itself

Abstract

Tauopathies are neurodegenerative diseases that involve tau misfolding and aggregation in the brain. These diseases, including Alzheimer's disease (AD), are some of the least understood and most difficult to treat neurodegenerative disorders. Antibodies and antibody fragments that target tau oligomers, which are especially toxic forms of tau, are promising options for immunotherapies and diagnostic tools for tauopathies. In this study, we have developed conformational, tau oligomer-specific nanobodies, or single-domain antibodies. We demonstrate that these nanobodies, OT2.4 and OT2.6, are highly specific for tau oligomers relative to tau monomers and fibrils. We used epitope mapping to verify that these nanobodies bind to discontinuous epitopes on tau and to support the idea that they interact with a conformation present in the oligomeric, and not monomeric or fibrillar, forms of tau. We show that these nanobodies interact with tau oligomers in brain samples from AD patients and from healthy older adults with primary age-related tauopathy. Our results demonstrate the potential of these nanobodies as tau oligomer-specific binding reagents and future tauopathy therapeutics and diagnostics.

Indexed as

Alzheimer DiseaseSingle-Domain Antibodiestau ProteinsBrainEpitope MappingHumansProtein AggregatesProtein ConformationProtein AggregatesSingle-Domain Antibodiestau Proteins

Identifiers

PMID39434503
PMCPMC11585960

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.